oral glp-1 agonists GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies Anesthetic Considerations for Patients Taking

12.1% of other AOM users

Pediatric and Adolescent Obesity Treatment: Since FDA approval in 2022, GLP-1 receptor agonists have been prescribed for individuals aged 12 years and older with obesity (BMI 95th percentile)

Patients with a history of pancreatitis, certain thyroid cancers, or severe gastrointestinal disease may need alternative therapies

doi: 10.1186/s12902-021-00908-1 121 ShuaiYYangGZhangQLiWLuoYMaJet al

Finally, some research suggests that GLP-1 may also influence processes in the brain in a way that limits cravings and overeating

For patients with chronic kidney disease, heart failure, or established atherosclerotic cardiovascular disease, substituting a sodium-glucose cotransporter 2 (SGLT2) inhibitor may be preferred